» Articles » PMID: 28347282

Hyperuricemia After Orthotopic Liver Transplantation: Divergent Associations with Progression of Renal Disease, Incident End-stage Renal Disease, and Mortality

Overview
Journal BMC Nephrol
Publisher Biomed Central
Specialty Nephrology
Date 2017 Mar 29
PMID 28347282
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although hyperuricemia is common after orthotopic liver transplantation (OLT), its relationship to mortality, progressive kidney disease, or the development of end stage renal disease (ESRD) is not well-described.

Methods: Data from 304 patients undergoing OLT between 1996 and 2010 were used to assess the association of mean serum uric acid (UA) level in the 3-months post-OLT with mortality, doubling of creatinine, and ESRD incidence. Post-OLT survival to event outcomes according to UA level and eGFR was assessed using the Kaplan Meier method and multivariate Cox proportional hazards models.

Results: Mean UA level among the 204 patients with an eGFR level ≥60 ml/min/1.73 m was 6.4 mg/dl compared to 7.9 mg/dl among the 100 patients with eGFR <60 (p < 0.0001). During a median of 4.6 years of follow-up, mortality rate, doubling of creatinine, and ESRD incidence were 48.9, 278.2, and 20.7 per 1000 person-years, respectively. In the first 5 years of follow-up, elevated UA was associated with mortality (Hazard Ratio, HR = 1.7; p = 0.045). However, among those with eGFR ≥ 60, UA level did not predict mortality (HR = 1.0; p = 0.95), and among those with eGFR < 60, elevated UA was a strong predictor of mortality (HR = 3.7[1.1, 12.0]; p = 0.03). UA was not associated with ESRD, but was associated with doubling of creatinine among diabetics (HR = 2.2[1.1, 4.3]; p = 0.025).

Conclusion: In this post-OLT cohort, hyperuricemia independently predicted mortality, particularly among patients with eGFR < 60, and predicted doubling of creatinine among diabetics.

Citing Articles

Complications in Post-Liver Transplant Patients.

Agostini C, Buccianti S, Risaliti M, Fortuna L, Tirloni L, Tucci R J Clin Med. 2023; 12(19).

PMID: 37834818 PMC: 10573382. DOI: 10.3390/jcm12196173.


Risk factors and management of hyperuricemia after renal transplantation.

Zi X, Zhang X, Hao C, Wang Z Front Surg. 2023; 9:956213.

PMID: 36760666 PMC: 9904410. DOI: 10.3389/fsurg.2022.956213.


Expert consensus on management of metabolic disease in Chinese liver transplant recipients.

Shen T, Zhuang L, Sun X, Qi X, Wang Z, Li R World J Gastroenterol. 2020; 26(27):3851-3864.

PMID: 32774062 PMC: 7385566. DOI: 10.3748/wjg.v26.i27.3851.


Gout Due to Tacrolimus in a Liver Transplant Recipient.

Afridi S, Reddy S, Raja A, Jain A Cureus. 2019; 11(3):e4247.

PMID: 31131170 PMC: 6516587. DOI: 10.7759/cureus.4247.

References
1.
Liese A, Hense H, Lowel H, Doring A, Tietze M, Keil U . Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology. 1999; 10(4):391-7. DOI: 10.1097/00001648-199907000-00006. View

2.
Pagonas N, Kor S, Seibert F, Giese A, Zidek W, Reinke P . Effects of Treatment of Asymptomatic Hyperuricemia on Graft Survival and Mortality in Kidney Transplant Recipients. Ann Transplant. 2016; 21:350-9. DOI: 10.12659/aot.896821. View

3.
Matsuo H, Nakayama A, Sakiyama M, Chiba T, Shimizu S, Kawamura Y . ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload. Sci Rep. 2014; 4:3755. PMC: 3895923. DOI: 10.1038/srep03755. View

4.
Johnson R, Nakagawa T, Jalal D, Sanchez-Lozada L, Kang D, Ritz E . Uric acid and chronic kidney disease: which is chasing which?. Nephrol Dial Transplant. 2013; 28(9):2221-8. PMC: 4318947. DOI: 10.1093/ndt/gft029. View

5.
Feig D, Kang D, Johnson R . Uric acid and cardiovascular risk. N Engl J Med. 2008; 359(17):1811-21. PMC: 2684330. DOI: 10.1056/NEJMra0800885. View